A cluster randomized controlled trial of Uyghur medicine combined with carpotriol ointment in the treatment of mild to moderate psoriasis vulgaris
- Conditions
- psoriasis vulgaris
- Registration Number
- ITMCTR2023000042
- Lead Sponsor
- Hospital of Xinjiang Traditional Uyghur Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients with mild to moderate psoriasis vulgaris according to the diagnostic criteria.
(2) PASI score<10 points, BSA<10%, DLQI<10 points.
(3) According to the analysis of Uyghur medicine differentiation, patients with psoriasis vulgaris who meet the diagnosis of salty mucus.
(4) Age range from 18 to 65 years old.
(5) Informed consent, voluntary testing
(1) Tuberculosis and tumor patients.
(2) Combined with severe cardiac insufficiency, severe primary diseases such as liver and kidney systems. (Note: ALT and AST exceed the upper limit of the normal range by 2 times, while Cr exceeds the upper limit of the normal range.)
(3) Have taken steroids or any medication to treat psoriasis within the past 2 weeks; Have taken retinoic acid drugs or topical steroid preparations and any topical medication for the treatment of psoriasis within one week.
(4) Plan for pregnant, pregnant, or lactating women.
(5) Suspected or confirmed history of alcohol or drug abuse.
(6) Allergic constitution (allergic to two or more other drugs), or allergic to the drug components in this plan.
(7) Other situations that may reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the work environment, mental disorders, communication difficulties, etc., are deemed unsuitable by the researchers to participate in this clinical trial.
(8) Individuals who have participated in clinical trials of other drugs within the past month or are currently participating in other clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method psoriasis area and severity index,PASI;
- Secondary Outcome Measures
Name Time Method yghur Medical Syndrome Score;Post effect of 18 weeks;Dermatology Life Quality Index, DLQI;Affected area of body surface,BSA;